Please login to the form below

Not currently logged in
Email:
Password:

Fresenius

This page shows the latest Fresenius news and features for those working in and with pharma, biotech and healthcare.

Data integrity scuppers Fresenius deal with Akorn

Data integrity scuppers Fresenius deal with Akorn

Fresenius raised the data integrity question and said it was launching an investigation into the matter. ... After completing its probe, Fresenius says the breaches were sufficiently serious to allow it to exit the agreement.

Latest news

More from news
Approximately 7 fully matching, plus 22 partially matching documents found.

Latest Intelligence

  • KAM 2.0 KAM 2.0

    The Fresenius Helios hospital group, based in Germany, recently acquired the Spanish hospital group Grupo Hospitalario Quirónsalud to become the largest hospital group in Europe.

  • Pharma deals continue to slide Pharma deals continue to slide

    For example, Fresenius’s acquisition of NxStage Medical (US), a home dialysis competitor, for $2bn is being financed with cash and debt. ... Even so the Fresenius shareholders do not seem worried as the share price remained much the same after the

  • Deal Watch - May 2017 Deal Watch - May 2017

    following an announcement as seen with BD and Cardinal Health.  It is encouraging, therefore, to see Fresenius’s share price increase by 2% following the announcement that its subsidiary Fresenius Kabi ... 6, 100. Akorn (US). Fresenius (DE). Company

  • Deal Watch May 2016 Deal Watch May 2016

    The presence of the CRL on the books however did not deter Vifor Fresenius Medical Care Renal Pharma's decision to license Rayaldee [a vitamin D prohormone treatment] from OPKO paying ... 293. OPKO Health/ Vifor Fresenius. Licence. Rayaldee in EP, CA,

  • Pharma deals in August 2015 Pharma deals in August 2015

    Collaboration. 219. Relypsa. Vifor Fresenius. Patiromer oral suspension in treating hyperkalemia.

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest appointments

  • Hikma appoints group scientific officer and global head of R&D Hikma appoints group scientific officer and global head of R&D

    He joins the pharma group from Fresenius Kabi, where he most recently led its US innovation and development centre. ... Prior to this, he served as chief scientific officer for Sabur Pharma, an oncology company that was acquired by Fresenius in 2008.

  • Galenica Group strengthens management team Galenica Group strengthens management team

    Currently chief executive of Vifor Fresenius Medical Care Renal Pharma (VFMCRP), Schulze (pictured right) will take up his new roles in May 2017 reporting to Etienne Jornod, executive chairman of the ... development at Fresenius Medical Care for North

  • Zytoprotec expands supervisory board Zytoprotec expands supervisory board

    He served as vice president of biosciences at Fresenius Medical Care, a medical devices and services firm, as well as its global scientific ambassador between 1996 and 2013.

  • Bartenbach adds to healthcare management team Bartenbach adds to healthcare management team

    Anja Treiber has worked with CSL Behring, Novo Nordisk, Fresenius Kabi and Merz Pharma. ... In the last two years, Treiber has focused on international pharma clients including CSL Behring, Novo Nordisk, Fresenius Kabi and Merz Pharma.

  • Par hires Antonio Pera as commercial head Par hires Antonio Pera as commercial head

    His positions prior to joining JHP include senior VP, supply chain management at AmerisourceBergen Corporation, and senior management positions at Fresenius Kabi Pharmaceuticals, Oakwood Laboratories and Bedford Laboratories.

More from appointments
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics